New respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosis

Pharmaceutical Research

Volumn 29, Issue 10, 2012, Pages 2845-2859

  Duret, Christophe ^a   Wauthoz, Nathalie ^a   Sebti, Thami ^b   Vanderbist, Francis ^b   Amighi, Karim ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b Laboratoires SMB SA   (Belgium)

Author keywords

Dry powder for inhalation (DPI); Invasive aspergillosis; Itraconazole; Mannitol; Polymorphism

Indexed keywords

ITRACONAZOLE; MANNITOL; PHOSPHOLIPID;

AEROSOL; ARTICLE; CHEMICAL COMPOSITION; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SOLUBILITY; DRY POWDER; INHALATIONAL DRUG ADMINISTRATION; LUNG ASPERGILLOSIS; PARTICLE SIZE; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; INVASIVE PULMONARY ASPERGILLOSIS; ITRACONAZOLE; MANNITOL; MICROSCOPY, ELECTRON, SCANNING; PARTICLE SIZE; PHOSPHOLIPIDS; POWDERS; SOLUBILITY; SOLUTIONS; X-RAY DIFFRACTION;

EID: 84866729458     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0779-4     Document Type: Article

References (49)

1. Mcneil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, Warnock DW. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 2001;33:641-7.
2. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26:781-803.
3. Hope WW. Invasion of the alveolar-capillary barrier by Aspergillus spp.: therapeutic and diagnostic implications for immunocompromised patients with invasive pulmonary aspergillosis. Med Mycol. 2009;47 Suppl 1:S291-8.
4. HopeWW, Billaud EM, Lestner J, Denning DW. Therapeutic drug monitoring for triazoles. Curr Opin Infect Dis. 2008;21:580-6.
5. Coronel B, Levron JC, Dorez D, Van Devenne A, Archimbaud E, Mercatello A. Itraconazole lung concentrations in haematological patients. Mycoses. 2000;43:125-7.
6. Hoeben BJ, Burgess DS, McConville JT, Najvar LK, Talbert RL, Peters JI, Wiederhold NP, Frei BL, Graybill JR, Bocanegra R, Overhoff KA, Sinswat P, Johnston KP, Williams RO. In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2006;50:1552-4.
7. Alvarez CA, Wiederhold NP, McConville JT, Peters JI, Najvar LK, Graybill JR, Coalson JJ, Talbert RL, Burgess DS, Bocanegra R, Johnston KP, Williams RO. Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J Infect. 2007;55:68-74.
8. Chan HK. Dry powder aerosol delivery systems: current and future research directions. J Aerosol Med. 2006;19:21-7.
9. Amidon GL, Lennernas H, Shah VP, Crison Jr. A theoretical basis for A biopharmaceutic drug classification -the correlation of in-vitro drug product dissolution and in-vivo bioavailability. Pharm Res. 1995;12:413-20.
10. Yang W, Tam J, Miller DA, Zhou J, McConville JT, Johnston KP, Williams RO. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int J Pharm. 2008;361:177-88.
11. Tran CL, Buchanan D, Cullen RT, Searl A, Jones AD, Donaldson K. Inhalation of poorly soluble particles. II. Influence of particle surface area on inflammation and clearance. Inhal Toxicol. 2000;12:1113-26.
12. Jones RM, Neef N. Interpretation and prediction of inhaled drug particle accumulation in the lung and its associated toxicity. Xenobiotica. 2012;42:86-93.
13. Bindu MB, Kusum B, Banji D. Novel strategies for poorly water soluble drugs. Int J Pharm Sci Rev Res. 2010;4:76-84.
14. Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392:1-19.
15. Duret C, Wauthoz N, Sebti T, Vanderbist F, Amighi K. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties. Int J Pharm. 2012;428(1-2):103-13.
16. Weers JG, Tarara TE, Clark AR. Design of fine particles for pulmonary drug delivery. Expert Opin Drug Deliv. 2007;4 (3):297-313.
17. Shah B, Kakumanu VK, Bansal AK. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J Pharm Sci. 2006;95:1641-65.
18. Chung FH. Quantitative interpretation of X-ray diffraction patterns of mixtures. II. Adiabatic principle of X-ray diffraction analysis of mixtures. J App Cryst. 1974;7:526-31.
19. Wandt MA, Rodgers AL. Quantitative X-ray diffraction analysis of urinary calculi by use of the internal-standard method and reference intensity ratios. Clin Chem. 1988;34:289-93.
20. Galunin E, Vidal M, Alba MD. The effect of polymorphic structure on the structural and chemical stability of yttrium disilicates. Am Mineral. 2011;96:1512-20.
21. Morris G, Kokki MH, Anderson K, Richardson MD. Sampling of Aspergillus spores in air. J Hosp Infect. 2000;44:81-92.
22. Shah VP, Tsong Y, Sathe P, Liu JP. In vitro dissolution profile comparison-statistics and analysis of the similarity factor, f2. Pharm Res. 1998;15:889-96.
23. Weiler C, Egen M, Trunk M, Langguth P. Force control and powder dispersibility of spray dried particles for inhalation. J Pharm Sci. 2010;99:303-16.
24. Miao S, Roos YH. Crystallization kinetics and x-ray diffraction of crystals formed in amorphous lactose, trehalose, and lactose/trehalose mixtures. J Food Sci. 2005;70:E350-8.
25. Hulse WL, Forbes RT, Bonner MC, Getrost M. The characterization and comparison of spray-dried mannitol samples. Drug Dev Ind Pharm. 2009;35:712-8.
26. Elversson J, Millqvist-Fureby A. Particle size and density in spray drying -effects of carbohydrate properties. J Pharm Sci. 2005; 94:2049-60.
27. Sebti T, AmighiK. Preparationandin vitro evaluation of lipidic carriers and fillers for inhalation. Eur J Pharm Biopharm. 2006;63:51-8.
28. Kaialy W, Martin GP, Ticehurst MD, Momin MN, Nokhodchi A. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient. Int J Pharm. 2010;392:178-88.
29. Burger A, Henck JO, Hetz S, Rollinger JM, Weissnicht AA, Stottner H. Energy/temperature diagram and compression behavior of the polymorphs of D-mannitol. J Pharm Sci. 2000;89:457-68.
30. Hulse WL, Forbes RT, Bonner MC, Getrost M. Influence of protein on mannitol polymorphic form produced during co-spray drying. Int J Pharm. 2009;382:67-72.
31. Ostwald W. Studien uber die bildung und Umwandlung fester Korper. Z Phys Chem. 1897;22:289.
32. Khoshkhoo S, Anwart J. Crystallization of polymorphs: the effect of solvent. J Phys D: Appl Phys. 1993;26:890-3.
33. Yoshinari T, Forbes RT, York P, Kawashima Y. Moisture induced polymorphic transition of mannitol and its morphological transformation. Int J Pharm. 2002;247:69-77.
34. Alves GP, Santana MHA. Phospholipid dry powders produced by spray drying processing: structural, thermodynamic and physical properties. Powder Technol. 2004;145:139-48.
35. Iida K, Hayakawa Y, Okamoto H, Danjo K, Leuenberger H. Evaluation of flow properties of dry powder inhalation of salbutamol sulfate with lactose carrier. Chem Pharm Bull. 2001;49:1326-30.
36. Larhrib H, Martin GP, Marriott C, Prime D. The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int J Pharm. 2003;257:283-96.
37. Zhang Y, Wang XL, Lin X, Liu XL, Tian B, Tang X. High azithromycin loading powders for inhalation and their in vivo evaluation in rats. Int J Pharm. 2010;395:205-14.
38. Bosquillon C, Rouxhet PG, Ahimou F, Simon D, Culot C, Preat V, Vanbever R. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J Control Release. 2004;99:357-67.
39. Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E, Losem C, Sauerbruch T, Marklein G, Schmidt-Wolf IG. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses. 1999;42: 443-51.
40. Berenguer J, Ali NM, Allende MC, Lee J, Garrett K, Battaglia S, Piscitelli SC, Rinaldi MG, Pizzo PA, Walsh TJ. Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother. 1994;38:1303-8.
41. Pfaller MA, Messer SA, Hollis RJ, Jones RN. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002;46:1032-7.
42. Osaki T, Hanagiri T, Nakanishi R, Yoshino I, Taga S, Yasumoto K. Bronchial arterial infusion is an effective therapeutic modality for centrally located early-stage lung cancer: results of a pilot study. Chest. 1999;115:1424-8.
43. Lee YY, Wu JX, Yang M, Young PM, van Den BF, Rantanen J. Particle size dependence of polymorphism in spray-dried mannitol. Eur J Pharm Sci. 2011;44:41-8.
44. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, Mellado E, Donders AR, Melchers WJ, Verweij PE. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5: e219.
45. Mortensen KL, Johansen HK, Fuursted K, Knudsen JD, Gahrn-Hansen B, Jensen RH, Howard SJ, Arendrup MC. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility. Eur J Clin Microbiol Infect Dis. 2011;30:1355-63.
46. Verweij PE, Howard SJ, Melchers WJ, Denning DW. Azoleresistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist Updat. 2009;12:141-7.
47. Misra R, Malik A, Singhal S. Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species. Indian J Pathol Microbiol. 2011;54:112-6.
48. Wauthoz N, Deleuze P, Saumet A, Duret C, Kiss R, Amighi K. Temozolomide-based dry powder formulations for lung tumorrelated inhalation treatment. Pharm Res. 2011;28:762-75.
49. Six K, Verreck G, Peeters J, Brewster M, Van den Mooter G. Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fastand slow-dissolving polymers. J Pharm Sci. 2004;93:124-31.